07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

Dimericine T4N5 liposome lotion regulatory update

FDA granted Fast Track designation for AGI's Dimericine to treat solar and ultraviolet photosensitivity in patients with Xeroderma pigmentosum. The company hopes to submit an NDA for the DNA repair enzyme T4 endonuclease V liposomal...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Company News

AGI Dermatics management update

AGI Dermatics Inc. , Freeport, N.Y.   Business: Dermatology   Hired: Robert Van Nostrand as EVP and CFO, formerly SVP and chief compliance officer at OSI Pharmaceuticals Inc.  ...
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

AGI Dermatics preclinical data

Data from cultured human keratinocytes and dermal fibroblasts showed that mRNA synthesis and transcription of OCTN-1 (EGT's endogenous receptor) were measurable in both cell types. Additionally, EGT-treated cells showed lower levels of hydroxyl radicals vs....
07:00 , May 16, 2001 |  BC Extra  |  Company News

AGI Dermatics, Elan in skin cancer deal

The companies formed a joint venture to develop and market AGI Dermatics' Dimericine topical treatment, which contains a DNA repair enzyme that reverses UV-damaged DNA in the skin. ELN will invest $4 million in AGI...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Company News

Applied Genetics Inc. Dermatics other research news

AGI Dermatics received two SBIR grants from the National Cancer Institute. The first is a $100,000 Phase I grant to develop a second generation version of the company's T4N5 liposomes, which are in Phase III...